Cytomegalovirus reactivation in "immunocompetent" patients: A call for scientific prophylaxis

Journal of Infectious Diseases

Volumn 196, Issue 9, 2007, Pages 1273-1275

  Cook, Charles H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

CELL FUNCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EDITORIAL; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; T LYMPHOCYTE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; IMMUNOLOGY; NOTE; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPETENCE; SEPSIS; VIRAL LOAD; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 38449090302     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522433     Document Type: Editorial

References (24)

1. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. J Clin Virol 2002; 25(Suppl 2):S123-36.
2. Staras SAS, Dollard SC, Radford KW, Dana Flanders W, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143-51.
3. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26:1076-82.
4. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001; 29:541-7.
5. von Müller L, Klemm A, Weiss M, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 2006; 12:1517-22.
6. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005; 127:233-41.
7. Cook CH, Zhang X, McGuinness BJ, Lahm MC, Sedmak DD, Ferguson RM. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 2002; 185:1395-1400.
8. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1β triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006; 80:9151-8.
9. von Müller L, Klemm A, Durmus N, et al. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis 2007; 176:1288-95 (in this issue).
10. Shellam GR, Allan JE, Papadimitriou JM, Bancroft GJ. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc Natl Acad Sci USA 1981; 78:5104-8.
11. Polic B, Hengel H, Krmpotic A, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998; 188:1047-54.
12. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Eng J Med 1989; 320:1731-5.
13. Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 1994; 179:185-93.
14. Simon CO, Holtappels R, Tervo H-M, et al. CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 2006; 80:10436-56.
15. Cook CH, Martin LC, Yenchar JK, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med 2003; 31:1923-9.
16. Cook CH, Yenchar JK, Kraner TO, Davies EA, Ferguson RM. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg 1998; 176:357-60.
17. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993; 67:5360-6.
18. Cook CH, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med 2006; 34:842-9.
19. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-80.
20. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
21. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
22. + T lymphocytes in healthy seropositive donors. J Virol 2000; 74:8140-50.
23. Komatsu H, Sierro S, Cuero AV, Klenerman P. Population analysis of antiviral T cell responses using MHC class I-peptide tetramers. Clin Exp Immunol 2003; 134:9-12.
24. Demmler GJ. Cytomegalovirus infection: back to the future or no more elephants? Clin Infect Dis 2006; 43:1152-3.